TOKYO -- Japanese pharmaceutical companies Daiichi Sankyo and Nichi-Iko, in cooperation with the University of Tokyo, will work to develop a potential inhalation treatment for the coronavirus, the parties announced Monday.
The project will focus on turning Nichi-Iko's protease inhibitor Futhan, a candidate treatment for COVID-19, into an inhalation preparation to make it more effective.
